welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
completed
CRD007 for the Treatment of Duchenne Muscular Dystrophy, Becker Muscular Dystrophy and Symptomatic Carriers
study id #: NCT01540604
condition: Duchenne Muscular Dystrophy , Becker Muscular Dystrophy
status: completed
purpose:This is an investigation of the efficacy and safety of CRD007 in Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD) and symptomatic carriers.
intervention: CRD007
mechanism of action: Non-steroidal agent to decrease inflammation
results: https://clinicaltrials.gov/ct2/show/results/NCT01540604
last updated: November 22, 2018
study details
study contacts
rareRelated
-
Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)This is a Phase 2, open-label, single ar...
-
A phase 2 trial of the safety and pharmacokinetics of ataluren in patients aged 2 to 5 years with nonsense mutation ...Nonsense mutation Duchenne muscular dyst...
-
Capricor Announces Positive Outcomes from Comprehensive Multidisciplinary Meeting with FDACapricor Therapeutics, a clinical-stag...
-
Capricor Therapeutics Announces Positive Results from its Interim Analysis in the HOPE-2 Trial to Treat Patients wit...Capricor Therapeutics, Inc. (NASDAQ: CAP...
-
Sunphenon Epigallocatechin-Gallate (EGCg) in Duchenne Muscular DystrophyThe aim of this multicentre, prospective...
-
Phase IIb Study of PRO045 in Subjects With Duchenne Muscular DystrophyThe purpose of the study is to see wheth...
-
Oral Ifetroban in Subjects With Duchenne Muscular DystrophyDuchenne muscular dystrophy (DMD) is a d...
-
Capricor places Duchenne drug trial on holdCapricor Therapeutics Inc said on Wednes...
-
FDA grants RASRx1902 orphan drug status as potential therapy for Duchenne muscular dystrophyThe U.S. Food and Drug Administration ha...
